Management of arthritis often necessitates the long-term use of disease-modifying agents such as methotrexate and tumor necrosis factor (TNF) inhibitors, which require careful monitoring of infection risks, drug resistance, and systemic side effects associated with immunosuppressive therapies [6]. Here, TNF is linked to arthritic joint disease.